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at presentation have not been investigated so far in HLH.
Hence, we decided to retrospectively analyze lymphocyte
subsets and quantitative immunoglobulin levels in addi-
tional to traditional diagnostic markers at presentation in
patients with HLH.
Methods: We retrospectively analyzed the medical records
of patients who received a diagnosis of HLH at our institu-
tion, believed to be familial or secondary HLH. Patients with
SAP deﬁciency were excluded as hypogammaglobulinemia is
a known association. Patients who had received HLH therapy
prior to evaluation of lymphocyte subsets and immuno-
globulin levels were also excluded from the analysis. Data at
presentation was evaluable in 35 patients.
Results: Of the 35 patients, 26 had familial HLH and 9 had
secondary HLH. 25 patients underwent allogeneic HSCT.
Seven died secondary to complications post HSCT and 1
patient died prior to HSCT from refractory HLH. Identiﬁable
genetic mutations associated with HLH were found in 20
patients. Analysis of their immune phenotype in additional
to the diagnostic criteria revealed the following: 19(54%)
had B-cell lymphopenia, including 7(20%) who had both
T-cell and B-lymphopenia. 3(8%) patients had T-cell
lymphopenia. Even in patients with B and T cell lympho-
penia, the B-cell lymphopenia was proportionately lower.
Hypogammaglobulinemia (low IgG levels) was seen in 4
patients.
Discussion: Although we noted hypogammoglobulinemia in
a few patients, the predominant ﬁnding was the high inci-
dence of B-cell lymphopenia. Interestingly, B-cell lympho-
penia and hypogammaglobulinemia have also been noted
perforin deﬁcient mice with HLH at our institution (unpub-
lished data). In conclusion, this study suggests that B-cell
lymphopenia can serve as a surrogate marker for the diag-
nosis of HLH.243
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Umbilical cord blood (UCB) has been shown to contain suf-
ﬁcient progenitor cells to provide durable engraftment in
children, and it provides an alternative stem cell source for
patients without matched related or unrelated donors.
We describe the preliminary results of a cohort of 16 pedi-
atric patients with a median age of 9 years (range 3 -18) with
haematological malignancies undergoing to a unrelated
umbilical cord blood transplant with a reduced-intensity
conditioning regimen of ﬂudarabine, melphalan, and
antithymocyte globulin.
All patients achieved hematologic recovery, the median
time to an absolute neutrophil count > 0.5 x 109/L was 20
days, and the median time to an unsupported platelet
count > 20 x 109/L was 32 days. Acute graft-versus-host
disease (GVHD) grade III-IV occurred in 37,5% of patients.
The 100-day TRM was 25%, and the 1 -year disease-free
survival was 58%.
Our ﬁndings support the use of reduced-intensity regimen in
pediatric patients with hematologic malignancies, however
the incidence of acute GVHD is a little higher than that re-
ported in other series so a better strategy for prophylaxis
against acute GVHD should be implemented.244
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X-linked adrenoleukodystrophy (X-ALD) is a demyelinating
disease caused by the deﬁciency of the ABCD1 gene that
encodes for a peroxisomal protein membrane. The most se-
vere form of X-ALD is the cerebral variant, which leads to
severe disability and death during the ﬁrst two decades. To
date, allogeneic hematopoietic stem cell transplantation
(HSCT) is the only treatment that has shown to signiﬁcantly
change the natural history of the disease, enhancing survival
and stabilizing neurological lesions and symptoms. In the
absence of a matched sibling or unrelated donor, hap-
loidentical family members might be an option in these
rapidly progressing diseases. Haploidentical HSCT has been
performed using a T cell depleted graft, but is often associ-
ated with higher rates of graft failure and delayed immune
reconstitution. Haploidentical HSCT using post-transplant
cyclophosphamide has been performed in series of malig-
nant and non-malignant diseases and has shown similar
outcomes compared to other alternative donor sources. Here
we show our experience with 8 patients with X-ALD treated
with haploidentical HSCT with post-transplant cyclophos-
phamide. Between november 2012 and august 2013, 8
patients with X-ALD (ages 6 to 18 years) underwent hap-
loidentical related HSCT in two different institutions, two
patients received two transplants with different related do-
nors. One patient received a second transplant after failure of
a double cord blood transplant. Pre-transplant MRI showed
Loes score of 2,5 to 18, all patients had neuropsychological
evaluation with performance IQ above 90. Donor was the
father (n¼7), the uncle (n¼2) or brother (n¼1). All patients
received reduced toxicity conditioning regimen consisted of:
ﬂudarabine 150 mg/m2, cyclophosphamide 29 mg/kg and
total body irradiation 2 Gy. Six patients received also rabbit
antithymocyte globulin 4,5 mg/kg. GVHD prophylaxis con-
sisted of cyclophosphamide 50 mg/kg/d on days +3 and +4,
tacrolimus and mycophenolate mofetil starting on day +5.
Seven patients engrafted, 13 to 19 days after transplant. One
patient had a primary graft failure and was not eligible for a
second transplant due to severe progression of neurological
symptoms. Two patients had secondary graft failure with
progressive loss of donor chimerism and were successfully
rescued with second haploidentical transplants using
different related donors. Four patients had grade II-IV acute
graft-versus-host disease and four patients had CMV reac-
tivations. One patient with grade III GVHD showed progres-
sion of neurologic symptoms of primary disease. Seven
patients are alive and engrafted from 3 to 11 months after
